Plasma Services Group Announces Ability to Meet Significant Growth in Demand for Disease-State Products

Company Skillsets Match Growing Demand in Market

Plasma Services Group (PSG), a leading provider of disease-state plasma and biological material for in-vitro diagnostics, biobanking, and biological research, is thrilled to announce a 65% increase in revenue in 2024. This growth was driven by PSG’s strategic initiatives focused on the utilization of its new FDA-registered, ISO-certified facility, expansion of its unique donor recruitment program and the addition of key leadership to address more of the industry’s demand. PSG’s investments are anticipated to continue supporting rapid growth in customer needs into 2025 and 2026.

PSG's leadership team is committed to building a stable foundation in recruiting, biobanking, bulk plasma, and services, which will enable the company to invest in growth and innovation. “It is so great to see how all the work over the years has led us to this point where we can finally spread our wings”, says Nichelle Fernandez, President of PSG. She feels confident in PSG’s future and states that “our customers have put so much faith in us to deliver on unprecedented demand, and we feel that we will be able to deliver.”

The diagnostics supply market has become increasingly constricted due to raw material supply complications. PSG specializes in the autoimmunity sector where these supply pressures are common. While the diagnosis of autoimmune conditions rises across the global population the availability of this biological material used by the diagnostic manufacturers is inversely falling.

To see what PSG can do for your organization please contact sales/marketing at tcrowley@plasmaservicesgroup.com.

PSG offers a comprehensive suite of services, including donor recruitment, biobank and bulk sera inventory, and laboratory experience. PSG also provides CRO services that cross functionally utilize their experience in donor recruitment, biobank and bulk sera inventory, and laboratory experience. The company is in Moorestown, NJ where it performs its donor recruitment, operations, and laboratory activities.

PSG’s mission is to deliver top-quality biological material while upholding integrity, curiosity, and efficiency. They aim to address sample accessibility issues with technical expertise and customer-centricity. PSG envisions accelerating research advancements and strives to build a reputation synonymous with the highest standards of integrity.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250217087057/en/